NeuroTalk Support Groups - V81444, Phase 1 / A2A receptor agonist

NeuroTalk Support Groups (https://www.neurotalk.org/)

- Parkinson's Disease Clinical Trials (https://www.neurotalk.org/parkinson-s-disease-clinical-trials/)

- - V81444, Phase 1 / A2A receptor agonist (https://www.neurotalk.org/parkinson-s-disease-clinical-trials/155908-v81444-phase-1-a2a-receptor-agonist.html)

V81444, Phase 1 / A2A receptor agonist

Vernalis Initiates Phase I Trial of V81444 for Parkinson’s Disease

cisionwire, 24 August 2011

Vernalis plc today announces it has dosed the first subjects in a Phase I trial of V81444, its adenosine A receptor antagonist programme. A receptor antagonists are believed to have advantages over conventional dopaminergic strategies, in that they may be able to help restore motor function in patients with Parkinson’s Disease (PD), without the side effects commonly associated with today’s treatments.